Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
The company says the new facility will allow Lilly to research new ways of producing medicines while scaling up the manufacturing of medicines for clinical trials.On Wednesday, Eli Lilly And Co. (NYSE:LLY) announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.
礼来（纽交所:LLY）周三宣布投资45亿美元，建立爱文思控股医药制造基地，这将是一家新型先进制造和研发药品的中心。
As the company inches closer to becoming the first pharma company in the $1 trillion club, it aims to strengthen its standing as one of the top 10 most valuable firms in the U.S. by outpacing its competitors.
作为公司距离成为万亿美元俱乐部中的第一家药品公司越来越近，它旨在通过超越竞争对手，巩固自己作为美国前十大最有价值公司之一的地位。
In a report, Eli Lilly said it plans to reinvest its revenues into R&D, aiming to escape the pharmaceutical industry's traditional boom-and-bust cycle.
据报道，礼来表示计划将收入重新投资于研发，以摆脱药品行业传统的繁荣与萧条循环。
The company says the new facility will allow Lilly to research new ways of producing medicines while scaling up the manufacturing of medicines for clinical trials.
公司表示，新设施将使礼来得以研究生产药品的新方法，并将其扩大到用于临床试验的药品制造规模。
Also Read: Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market.
另请参阅：礼来早期阿尔茨海默病治疗多纳莫莫（Donanemab）获得日本批准，其第二大市场。
The Medicine Foundry will be the first-ever facility of its kind to combine research and manufacturing in a single location. It will be located in Indiana's LEAP Research and Innovation District in Lebanon, Indiana, and will expand the company's investment there to more than $13 billion.
医药研究中心将是第一个将研究和制造结合在同一地点的设施，它将位于印第安纳州黎巴嫩的LEAP研究和创新区，将使公司在该地区的投资扩大到130亿美元以上。
This new facility will add to Lilly's previous manufacturing commitments in Lebanon, which include a $2.1 billion investment announced in May 2022 to expand its network for active ingredients and new modalities, such as genetic medicines.
这一新设施将补充礼来此前在黎巴嫩的制造承诺，包括2022年5月宣布的21亿美元投资，以扩大其活性成分和新模式（如基因药品）网络。
In April 2023, the company announced an additional $1.6 billion investment.
2023年4月，公司宣布再投资16亿美元。
In May 2024, Lilly announced an additional $5.3 billion commitment to enhance its capacity to manufacture active pharmaceutical ingredients for its latest diabetes and obesity medicines, marking the largest single investment in active pharmaceutical ingredients production in U.S. history.
2024年5月，礼来公司宣布再投资53亿美元，以增强其用于生产最新糖尿病和肥胖药物活性药品的能力，这标志着美国历史上对活性药品生产的最大单笔投资。
Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more than $23 billion since 2020. It is trying to stay ahead of its close competitor, Novo Nordisk A/S (NYSE:NVO).
该设施计划于2027年底投入使用，将使礼来公司自2020年以来在美国的总资本承诺超过230亿美元。公司正努力在靠近的竞争对手诺和诺德生物制药股份有限公司（NYSE：NVO）之前取得领先地位。
Once fully operational, the Medicine Foundry is expected to add 400 full-time jobs.
一旦全面运营，Medicine Foundry预计将增加400个全职工作岗位。
Price Action: At last check on Wednesday, LLY stock was down 0.39% at $881.00 during the premarket session.
股价走势：最新数据显示，礼来股票在周三的盘前交易中下跌了0.39%，报881.00美元。
- Eli Lilly Nears First Trillion Dollar Pharma Title, But Investors Caution Amid Sky-High Valuation
- 礼来公司接近首个万亿美元药品行业市值称号，但投资者在估值飙升之际表示谨慎。
Photo via Shutterstock
图片来自shutterstock。
